NCT03462121View on ClinicalTrials.gov

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 28, 2019

Study Completion Date

March 30, 2020

Conditions

Mild to Moderate Dementia Due to Alzheimer's DiseaseWith or Without Coexisting Cerebrovascular Disease

Interventions

DRUG

RPh201

RPh201 is a well-defined extract from a botanical source

OTHER

Placebo

Inactive placebo consisting of the therapeutic vehicle

Trial Locations (5)

K9H 2P4

Kawartha Centre - Redefining Healthy Aging, Peterborough

M3B 2S7

Toronto Memory Program, Toronto

M4G 3E8

Gerontion Research Inc., The Center for Memory & Aging, Toronto

J8T 8J1

Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Memoire de l'Outaouais, Gatineau

J1L 0H8

Diex Recherche Sherbrooke Inc., Sherbrooke

All Listed Sponsors

lead

Regenera Pharma Ltd

INDUSTRY

NCT03462121 - A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease | Biotech Hunter | Biotech Hunter